This underscores that combining CDK4/6 inhibitors with other therapies, including regulation of cyclin D1 and other G1/S cyclins, inhibition of PI3K or mTORC1, opens a new path to develop novel strategies treating ER+ BC.6, 50, 51. Here, CDK4 is linked to breast cancer.